All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication
Recent regulatory changes and future outlook The regulatory landscape is evolving
Knowles, H
The product values were calculated on HPLC peak areas and integrated with OriginPro 8.5 software (Northampton, MA, USA)
Li W, Cai R, Yin B, et al
The combined action of GLP-1 and GLP-3 provides an additive effect on insulin secretion, improving glycemic control in type 2 diabetes, which is useful in the development of combination drugs